Search Results

Sexton , Denise Wootten , et al., for their work on Isoquinoline small molecule ligands are agonists

Denise Wootten and colleagues has highlighted the importance of extracellular loop 2 (ECL2) in stabilizing Wootten, D., et al., The Extracellular Surface of the GLP-1 Receptor Is a Molecular Trigger for Biased

Decisions stall. And momentum quietly dies. GPCR, I’m connected to 1,300+ scientists and decision-makers worldwide. you move faster—with fewer blind spots, tighter execution, and a clear line of sight to your next key decision teams don’t need more data— they need clarity ✅ Yamina’s Corner helps teams move from data chaos to decisive

Strong GPCR drug discovery decisions are built on structure, early risk awareness, and focused signal Each piece is designed to help you make better decisions—faster. 🔍 This Week in Premium: Sneak Peek This soft launch prioritizes usability and clarity to support stronger GPCR drug discovery decisions It equips leaders making strategic and capital decisions. When decisions compound, scattered information creates drag.Structured access creates momentum.

the frameworks needed to interpret data correctly, eliminate wasted effort, and accelerate confident decisions

Early in the year, decisions feel small. Flexible. Reversible. This is the true domain of strategic decision-making . Early decisions set the direction long before outcomes appear. How Alignment Turns Decisions into Real Progress Strategic decisions only matter if they translate into   👉 Good strategic decision-making leaves room for learning.

crafted for pharmacologists and biotech scientists who need to translate mechanistic nuance into better decision-making Map dynamic receptor behavior to real-time decision-making.   Sharpen your discovery decisions ➤ GPCR Signal Transduction Call for Papers: Define What Comes Next Volume GPCRs across translational pharmacology, drug development, or molecular pharmacology, this is your decision GPCR scientists, translational pharmacologists, biotech drug discovery teams, and decision-makers who

equilibrium curves are your comfort zone, this week’s feature will challenge (and strengthen) your decisions conformation of GLP‑1 receptor Terry's Corner – Advanced Applications of GPCR Kinetics for Real-World Decision These are the pattern-recognition tools that convert uncertainty into decisions you can defend at a project GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need

research requires turning data into insights for drug discovery Hi GPCR Friends, Every week, critical decisions statistical tests actually answer the question you think you’re asking—so you can start making confident decisions GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need

How Rational Decisions Accumulate Into Drift 👉 Every biotech startup is built on decisions that make Each decision is rational in isolation, yet no one steps back to evaluate how those decisions interact No single decision feels reckless. Decisions take longer because the context is unclear. the pattern those decisions create over time.

Hiring decisions are pulled forward to support a story. Hiring decisions are accelerated to signal momentum.   Under these conditions, decision making begins to shift subtly. Decisions that reduce tension are prioritized over decisions that resolve it. 👉 The company does not Instead, clarity erodes quietly, decision by decision, under the assumption that everything will be fixed

Instead of explaining everything, they provide context for decisions. They are evaluating decisions. Where does this fit? What does it replace? It defines the decision frame before the science is introduced. When that decision is made explicitly, depth stops being a liability. They happen because the decision context becomes explicit .

Which decisions can we still reverse, and which ones are already locked in? Hiring decisions feel justified because the science is moving. They track burn rate, but not decision reversibility. It emerges gradually, through small changes in how decisions are made. The science continues, but the intent behind decisions changes.

The problem begins when they expand faster than the company’s ability to make clear decisions. Decisions become harder. Tradeoffs are postponed. of decisive moments weakens it. Scientists trust leadership because decisions are grounded in logic rather than mood. It makes priorities explicit, decisions visible, and tradeoffs intentional.

Wootten, D., et al., Allostery and Biased Agonism at Class B G Protein-Coupled Receptors.  

Internal meetings slowly morph into scientific colloquia instead of decision-making forums. 👉 The uncomfortable Systems (Do decisions only happen when new data appears?) In isolated companies, decisions are tethered to experimental data → no decisions. 👉 A functioning decision system introduces: clear thresholds default actions go/no-go moments ownership of decisions locked vs Bi-weekly refresh of BD and investor narratives A single, living source of truth for timelines and decisions

 in tissues like tumors slows offset and improves therapeutic window ✅ Examples of how rebinding in dense And when receptors are dense (like GPCRs on membranes), this rebinding hits the collisional limit , where down how to distinguish between true target persistence vs. sequestration, with clear takeaways for decision-making

But decisions lag, the team spins, and investors get nervous. But in business, decisions must be made under uncertainty . It requires conscious shifts in how you process uncertainty, how you frame decisions, and how you lead If you find yourself looping decisions or delegating them upward, you might be leaning on scientific It’s about realizing that your value now lies in decisions, not just in depth.    

And that cadence is shaping everything: timelines, decisions, investor calls, BD traction, internal focus When teams adopt structured decision cycles, consistent narrative checkpoints, and predictable timeline , Not Just What You Decide Founders often obsess over the content of decisions. But what kills momentum is timing inconsistency . 👉 Without a defined decision cadence: Choices get Decisions are made once and communicated clearly. 2️⃣ Cadence of Communication: The Rhythm That Builds

and last month, we’re back in full force—designed to help you make better scientific and strategic decisions It’s about better alignment : helping scientists, drug hunters, and decision-makers stay grounded in you need ➤ Terry’s Corner—Basic Pharmacokinetics Pharmacokinetics isn’t a late-stage checkbox—it’s a decision Leadership decisions  that keep multidisciplinary teams aligned. 👉 Listen to the full conversation ➤ GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need

insight designed to equip you to move beyond surface-level affinity data and make faster, more confident decisions Why Faster, Smarter Decisions Require More Than Kd In drug discovery today, the clock is always ticking Your pipeline depends on early, well-informed decisions that move promising candidates forward while of endogenous ligands— change kinetic behavior , and ignoring this can lead to wrong prioritization decisions Kenakin’s lecture guides you through key questions that should shape your decision-making process: Are

Decision-making slows. The narrative becomes broader but less decisive. When Everything Is Strategic, Nothing Is Decisive 👉 Strategic overload starts with reasonable decisions Without exclusion, the company appears broad but not decisive. It is solved by structural decisions. Externally, especially in biotech fundraising, it is decisive.

And when decisions ride on subtle shifts, “looks different” isn’t good enough. No more guesswork, only decisions you can trust. This ability transforms meetings from endless discussions to clear decisions. —becomes a black-and-white decision. Does Your Assay Agree With the Literature? s Corner Why Terry’s Corner Your work demands clarity, speed, and confidence, especially when early decisions

Teams feel busy, but outcomes feel less decisive. Leadership conversations take longer. In biotech, disciplined decisions today build strategic focus, execution clarity, and stronger biotech real at the decision level. If it does not clearly move the company toward the next decisive milestone, it likely dilutes attention When leaders consistently apply disciplined decision criteria, the organization gains confidence.

No one’s wrong, but no one’s aligned. 2️⃣ Founder-team decision asymmetry 👉 The founders make strategic Real biotech traction starts when decisions are driven by shared strategy, not disconnected deliverables A milestone is a decision point that moves your company in a strategic direction. Not progress. 👉 If your roadmap is full of scientific deliverables but empty of decision triggers, you But by making the decision framework visible across the team.  

binding experiments that advance your work efficiently ✅ Clarity that helps you move from assay to decision you’re working in drug discovery, you know the pressure: timelines are tight, resources finite, and decisions happening in a physiological context, and misunderstanding this can introduce inefficiency into your decision-making Interpret complex binding data correctly Separate what matters from what misleads Make confident, efficient decisions

questions about binding kinetics and experimental constraints, ensuring your analysis is robust and your decisions Sharpen your discovery decisions ➤ Yamina's Consulting Corner - Building Your GPCR Program for Breakthroughs Bridge science and strategy:  Ensure data and decision-making align with funding and milestones. GPCR scientists, translational pharmacologists, biotech drug discovery teams, and decision-makers who GPCR Premium Today The breakthroughs are happening now, and the decisions you make today will determine

Early hiring decisions are usually made around skills, experience, and domain expertise. Progress depends on decisions made with incomplete information. Decisions escalate upward. Founders feel the pressure to hold everything together. It only becomes visible once the science stops behaving, and decisions still need to be made. They know that waiting is also a decision. 2️⃣ Ownership without clear boundaries: When roles are still

This week’s edition links ligand mechanism to the decisions that shape affinity, efficacy, selectivity Each week we highlight the decisions that move GPCR projects forward—from pharmacology essentials to Win on kinetics, not just Kd:  Dynamic binding means “affinity” moves—design readouts and decisions that GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need Your team’s next good decision may start here 🚀 Join Premium Today & Enjoy ➤ 🎓 Full GPCR University

Community, If you work on GPCR discovery, you already know: early signals can mislead, and timing your next decision Terry Kenakin to elevate your science and sharpen your decisions. relevance:  Fluorescent ligands can retain receptor integrity—critical when signaling readouts drive decisions vetted job opportunities, and insider commentary—structured to help you move faster and make cleaner decisions pharmacology." — DrGPCR University Attendee Ready to turn ambiguous signals into confident, defensible decisions—and